Ilan Ganot compensation by year
Solid Biosciences Summary Compensation Table · all 5 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Salary | $400,000 | $450,000 | $520,000 | $535,000 | $551,100 |
| Bonus | $200,000 | $247,500 | $193,050 | $294,250 | $187,925 |
| Stock awards | $0 | $0 | $0 | $246,370 | $0 |
| Option awards | $0 | $5,286,270 | $2,622,879 | $405,382 | $2,544,780 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $10,004 |
| Total | $600,000 | $5,983,770 | $3,335,929 | $1,481,002 | $3,293,809 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Solid Biosciences Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-125475, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Solid Biosciences Inc. filed document, accession 0001193125-22-125475. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 77,500 | — | $22.93 |
| Option | 106,500 | — | $3.47 |
| Option | 438,000 | — | $6.80 |
| Option | 48,250 | — | $37.89 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Solid Biosciences Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
34 Form 4 lines since the FY2021 proxy (filed April 28, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-01 | Grant or award derivative | — | 150,000 | $0.00 | 150,000 |
| 2026-06-10 | Grant or award derivative | — | 77,500 | $0.00 | 77,500 |
| 2026-02-18 | Sale | 10b5-1 | 2,658 | $5.82 | 27,474 |
| 2026-02-13 | Exercise or conversion derivative | 10b5-1 | 4,861 | $0.00 | 9,722 |
| 2026-02-13 | Exercise or conversion | 10b5-1 | 4,861 | — | 30,132 |
| 2026-02-04 | Sale | 10b5-1 | 7,205 | $6.44 | 25,271 |
| 2026-01-31 | Exercise or conversion | 10b5-1 | 15,000 | — | 32,476 |
| 2026-01-31 | Exercise or conversion derivative | 10b5-1 | 15,000 | $0.00 | 45,000 |
The 8 most recent of 34 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Solid Biosciences’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Ilan Ganot · this page | President and Chief Executive Officer | $3,293,809 |
| Erin Brennan | Chief Legal Officer | $2,878,244 |
| Joel Schneider | Chief Operating Officer | $1,702,761 |
Board service
Solid Biosciences board · FY2023–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $40,000 | — | $297,685 | $0 | $337,685 |
| FY2024 | $40,000 | $0 | $224,204 | $241,145 | $505,349 |
| FY2023 | $40,000 | $0 | $54,221 | $807,867 | $902,088 |
Each year as the company reported it in Solid Biosciences's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Solid Biosciences pays directors a $40,000 cash retainer and $297,685 in equity. As stated in Solid Biosciences's FY2025 proxy.
The full Solid Biosciences compensation record
free company briefThis page is one person within Solid Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Solid Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.